NASDAQ:AUTL Autolus Therapeutics (AUTL) Stock Price, News & Analysis $4.67 +0.07 (+1.52%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$4.53▼$4.7750-Day Range$3.33▼$4.6052-Week Range$2.01▼$7.45Volume626,708 shsAverage Volume1.59 million shsMarket Capitalization$1.24 billionP/E RatioN/ADividend YieldN/APrice Target$8.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Autolus Therapeutics alerts: Email Address Autolus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside86.3% Upside$8.70 Price TargetShort InterestBearish4.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.78) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.57 out of 5 starsMedical Sector509th out of 936 stocksBiological Products, Except Diagnostic Industry77th out of 154 stocks 3.4 Analyst's Opinion Consensus RatingAutolus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAutolus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Autolus Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.47% of the outstanding shares of Autolus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAutolus Therapeutics has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Autolus Therapeutics has recently increased by 74.74%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUTL. Previous Next 2.5 News and Social Media Coverage News SentimentAutolus Therapeutics has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Autolus Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for AUTL on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.83% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Autolus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.78) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 7.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Autolus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Autolus Therapeutics Stock (NASDAQ:AUTL)Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Read More AUTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUTL Stock News HeadlinesJuly 26 at 7:00 AM | globenewswire.comAutolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024July 26 at 6:18 AM | americanbankingnews.comAutolus Therapeutics plc (NASDAQ:AUTL) Short Interest UpdateJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 18, 2024 | americanbankingnews.comShort Interest in Autolus Therapeutics plc (NASDAQ:AUTL) Expands By 5.9%June 14, 2024 | globenewswire.comAutolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) CongressJune 13, 2024 | investorplace.comStocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a BudgetMay 31, 2024 | globenewswire.comAutolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCOMay 25, 2024 | morningstar.comAutolus Therapeutics PLC ADRJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 22, 2024 | uk.investing.comWells Fargo Overweight on Autolus Therapeutics stock citing positive outlookMay 18, 2024 | finance.yahoo.comQ1 2024 Autolus Therapeutics PLC Earnings CallMay 17, 2024 | investorplace.comAUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024May 17, 2024 | finance.yahoo.comAutolus Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesMay 17, 2024 | globenewswire.comAutolus Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesMay 16, 2024 | markets.businessinsider.comHere's what to expect from Autolus Therapeutics's earnings reportMay 14, 2024 | seekingalpha.comAutolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An OpportunityMay 14, 2024 | globenewswire.comAutolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) CongressMay 13, 2024 | finance.yahoo.comAutolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference CallSee More Headlines Receive AUTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/17/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AUTL CUSIPN/A CIK1730463 Webwww.autolus.com Phone442038296230FaxN/AEmployees330Year FoundedN/APrice Target and Rating Average Stock Price Target$8.70 High Stock Price Target$11.00 Low Stock Price Target$4.80 Potential Upside/Downside+89.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-208,380,000.00 Net MarginsN/A Pretax Margin-2,107.98% Return on Equity-80.21% Return on Assets-41.47% Debt Debt-to-Equity RatioN/A Current Ratio18.29 Quick Ratio18.29 Sales & Book Value Annual Sales$1.70 million Price / Sales718.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book7.17Miscellaneous Outstanding Shares266,040,000Free Float197,665,000Market Cap$1.22 billion OptionableOptionable Beta2.11 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Christian Martin Itin Ph.D. (Age 60)CEO & Director Comp: $2.44MDr. Martin Pule M.D. (Age 52)MBBS, Founder, Senior VP & Chief Scientific Officer Mr. Robert F. Dolski (Age 53)Senior VP & CFO Mr. Christopher Vann (Age 59)Senior VP & COO Mr. David Brochu (Age 68)Senior VP & Chief Technical Officer Mr. Alexander Swan (Age 59)Senior VP & Chief Human Resources Officer Mr. Brent Rice (Age 58)Senior VP, Chief Commercial Officer & Site Head of US Ms. Olivia ManserDirector of Investor RelationsMr. Alex DriggsSenior VP of Legal Affairs & General Counsel and SecretaryDr. Chris Williams (Age 44)Senior VP & Chief Business Development Officer More ExecutivesKey CompetitorsImmunovantNASDAQ:IMVTImmunityBioNASDAQ:IBRXArcellxNASDAQ:ACLXTwist BioscienceNASDAQ:TWSTADMA BiologicsNASDAQ:ADMAView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 1,080,897 shares on 7/26/2024Ownership: 0.952%EWA LLCSold 6,562 shares on 7/24/2024Ownership: 0.007%LGT Capital Partners LTD.Sold 180,000 shares on 7/12/2024Ownership: 0.139%SG Americas Securities LLCBought 169,387 shares on 7/12/2024Ownership: 0.071%Lynx1 Capital Management LPSold 468,249 shares on 5/30/2024Ownership: 0.523%View All Institutional Transactions AUTL Stock Analysis - Frequently Asked Questions How have AUTL shares performed this year? Autolus Therapeutics' stock was trading at $6.44 on January 1st, 2024. Since then, AUTL shares have decreased by 27.5% and is now trading at $4.67. View the best growth stocks for 2024 here. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics plc (NASDAQ:AUTL) released its earnings results on Friday, May, 17th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.14. The company earned $10.09 million during the quarter, compared to analysts' expectations of $50 million. When did Autolus Therapeutics IPO? Autolus Therapeutics (AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. Who are Autolus Therapeutics' major shareholders? Top institutional shareholders of Autolus Therapeutics include Bank of New York Mellon Corp (0.95%), LGT Capital Partners LTD. (0.14%), SG Americas Securities LLC (0.07%) and EWA LLC (0.01%). How do I buy shares of Autolus Therapeutics? Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA) and TG Therapeutics (TGTX). This page (NASDAQ:AUTL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
